alexa
Reach Us +44-1904-929220
Next Generation Of Biomarkers: Serum Antibody Repertoire Profi Ling Using Next Generation Sequencing | 3643
ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Next generation of biomarkers: Serum antibody repertoire profi ling using next generation sequencing

2nd World Congress on Biomarkers & Clinical Research

Yurij Ionov

ScientificTracks Abstracts: J Mol Biomark Diagn

DOI: 10.4172/2155-9929.S1.2

Abstract
The promising idea of using serum antibodies for diagnosis of cancer is hampered by the heterogeneity of immune response against tumors and by low frequency of serum antibodies against particular autoantigens in cancer patients. Th e low diagnostic value of serum antibodies against tumor-associated autoantigens is the result of the limitations of the methods used for the detecting antibody responses. Current methods of antibody reactivity are designed for detecting high affi nity and/or high titer antibodies. However, a growing tumor may induce a variety of low affi nity and low titer autoantibodies which can not be detected by these methods. We developed a strategy for serum antibody repertoire profi ling, which allows detecting high affi nity/high titer as well as low affi nity/low titer autoantibodies in serum samples. Th is strategy, which we call virtual antigen array, is based on using random peptide phage display library panning on serum antibodies and NextGen sequencing of DNA from antibody bound phage. Th e iterative and amplifi cative nature of phage selection permits identifi cation of antibodies with a broad range of affi nities. Th e next generation sequencing of PCR amplifi ed DNA from antibody bound phage permits detection of binding of a single antibody to a single peptide. Th e identity of the autoantigens recognized by serum autoantibodies is identifi ed by using statistical analysis of BLAST homology search data for peptide sequences recognized by serum antibodies. Th e proposed strategy can be used for developing assays for early detection of cancer and prognosis of clinical outcomes and responses to therapies.
Biography
Yurij Ionov has completed his Ph.D at the Institute of Genetics and Selection of Industrial Microorganisms (Moscow, Russia). He did his postdoctoral studies at California Institute of Biological Research where he has made his contribution to the discovery of microsatellite instability in colon cancer. He is the Assistant Professor of Oncology at Roswell Park Cancer Institute in Buffalo NY.
Relevant Topics
Top